Hepatocellular carcinoma
Conditions
Interventions
Experimental group:PD-1/PD-L1 antibody
Control group:No PD-1/PD-L1 antibody
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 75 years old; 2) There was no history of serious arrhythmia and heart failure; 3) There was no history of severe ventilation dysfunction and severe pulmonary infection; 4) There was no acute or chronic renal failure. The creatinine clearance rate was more than 40 ml / min; 5) Good liver function: child Pugh grade A or B (= 28 g/L, AST, alt, ALP =1.5x10^9/L, Hb >=8.5 g/L, PLT >=75x10^9/L (no blood transfusion and drug treatment correction within 14 days before screening); 7) Coagulation function INR < = 2.3; 8) The pathological results were hepatocellular carcinoma (HCC); 9) Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) Those who have suffered from or are suffering from other malignant tumors; 3) Recurrent hepatocellular carcinoma; 4) Patients with mental illness were combined; 5) It is estimated that targeted drugs such as PD-1 monoclonal antibody sorafenib may be used after surgery; 6) Human immunodeficiency virus (HIV) carriers; 7) Patients with unresectable liver cancer or liver cancer who need liver transplantation; 8) Advanced hepatocellular carcinoma with systemic metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;Incidence of rejection reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease free survival; | — |
Countries
China
Contacts
Public ContactWang Zhengxin
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed